Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of researchers sheds light on the development of a new strategy for prevention of liver cancer.
While studying the pathogenic mechanisms of liver cancer, the researchers discovered that a commonly used synthetic double-stranded RNA (dsRNA) strongly boosts a variety of anti-tumor innate immune functions. They suggest it may have the potential to be administered as a vaccine to prevent cancer in individuals at high-risk of developing liver cancer.
"The liver has unique immune tolerance, which is why existing treatments, including immunotherapy, have little to no lasting effects on liver cancer," said senior author on the paper. "We were initially performing gene deletion to investigate how different types of cells communicate in the liver to promote or suppress cancer development when we found that this synthetic double-stranded RNA prevented liver cancer from initiating by harnessing the body's own innate immune system."
In the findings, published in Cell Reports, researchers describe how dsRNA polyinosinic-polycytidylic acid (pIC) prevented primary liver cancer from occurring in mouse models when it was injected into the body cavity during the pre-cancer stage. Primary liver cancer is cancer that begins in the liver; metastatic liver cancer starts elsewhere in the body and spreads to the liver.
The study showed that the formation of tumors -- or tumorigenesis -- was suppressed by reprogramming macrophages (specialized immune cells that destroy targeted cells) and activation of natural killer cells and dendritic cells that kill tumor cells directly or boost adaptive immunity.
Mouse models with tumors induced either by chemical carcinogen or fatty liver diseases were injected with pIC at different stages. Tumor inhibition was successful in all models that received the dsRNA before tumor formation. The greatest decrease in tumor numbers and size was seen when pIC was administered at one month. At three months the impact was reduced but still significant. At five months, when tumors had already began to form, there was little inhibitory effect observed when comparing tumor numbers or sizes to control groups.
Future studies will look at dosages and timing of pIC as a vaccine, said the senior author. In addition, the researchers will evaluate the use of pIC in combination with other agents to stop tumor growth when cancer has already initiated.
"The findings suggest that the drug may prevent liver cancer. We have more work to do, but we could make a real impact at a time when liver cancer rates are increasing," said the senior author. "There is a large population living with chronic liver disease who are at high risk of developing cancer. If we can develop a vaccine that prevents tumor formation or a therapeutic combination that stops existing cancer from growing, we could reduce the rapid increase of liver cancer rates."
http://ucsdnews.ucsd.edu/pressrelease/a_new_strategy_for_prevention_of_liver_cancer_development
http://www.cell.com/cell-reports/abstract/S2211-1247(17)31512-7
Latest News
Ancient viral DNA in the hu…
By newseditor
Posted 26 May
AI to analyze clumping prot…
By newseditor
Posted 26 May
Reversible, non-hormonal ma…
By newseditor
Posted 26 May
Dissection of the schizophr…
By newseditor
Posted 26 May
Protease action on controll…
By newseditor
Posted 25 May
Other Top Stories
Check-point inhibitors exacerbate NASH induced liver cancer
Read more
AI used to understand asbestos-linked cancer
Read more
Protein rewires cancer cell metabolism to promote metastasis
Read more
The role of hypoxia-inducible factors in tumor growth and suppression
Read more
Dual treatment to kill small cell lung cancer (SCLC) cells
Read more
Protocols
SEMORE: SEgmentation and MO…
By newseditor
Posted 26 May
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Publications
Integrating human endogenou…
By newseditor
Posted 26 May
The thalamic reticular nucl…
By newseditor
Posted 26 May
PMI-controlled mannose meta…
By newseditor
Posted 26 May
Protein-membrane interactio…
By newseditor
Posted 26 May
Toward an interventional sc…
By newseditor
Posted 26 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar